Blueprint Medicines Co. (NASDAQ:BPMC) Insider Ariel Hurley Sells 2,250 Shares

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) insider Ariel Hurley sold 2,250 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00. Following the sale, the insider now owns 14,967 shares in the company, valued at approximately $1,496,700. The trade was a 13.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Ariel Hurley also recently made the following trade(s):

  • On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Stock Performance

NASDAQ BPMC opened at $103.95 on Friday. The stock has a market cap of $6.60 billion, a PE ratio of -49.27 and a beta of 0.61. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The firm has a 50-day moving average of $93.85 and a 200-day moving average of $95.36. Blueprint Medicines Co. has a 52-week low of $72.24 and a 52-week high of $121.90.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business’s revenue was up 126.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.20) earnings per share. On average, sell-side analysts anticipate that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BPMC. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. JPMorgan Chase & Co. started coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price objective on the stock. UBS Group initiated coverage on shares of Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price target on the stock. Wells Fargo & Company reduced their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $122.72.

Read Our Latest Stock Analysis on BPMC

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP boosted its position in shares of Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after acquiring an additional 729,055 shares during the period. Millennium Management LLC raised its stake in Blueprint Medicines by 540.0% in the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock worth $67,646,000 after purchasing an additional 529,566 shares in the last quarter. 1832 Asset Management L.P. grew its position in shares of Blueprint Medicines by 200,159.4% during the 2nd quarter. 1832 Asset Management L.P. now owns 502,651 shares of the biotechnology company’s stock worth $54,176,000 after purchasing an additional 502,400 shares in the last quarter. State Street Corp increased its holdings in shares of Blueprint Medicines by 16.2% during the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after purchasing an additional 385,818 shares during the period. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Blueprint Medicines by 161.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock valued at $45,888,000 after buying an additional 306,079 shares in the last quarter.

Blueprint Medicines Company Profile

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Featured Articles

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.